Avanir cites 'en­cour­ag­ing' progress in PhI­II pro­gram for Alzheimer's ag­i­ta­tion

Avanir Phar­ma has chalked up a win for the first late-stage study for AVP-786 in Alzheimer’s ag­i­ta­tion, lay­ing the ground­work for a high-risk, high-re­ward Phase III pro­gram.

The Ot­su­ka sub­sidiary kept things gen­er­al, di­vulging on­ly that one of the two dos­es test­ed in the study in­duced a sig­nif­i­cant im­prove­ment for pa­tients with mod­er­ate-to-se­vere ag­i­ta­tion on the Co­hen-Mans­field Ag­i­ta­tion In­ven­to­ry; in the oth­er dose arm, im­prove­ment was “nu­mer­i­cal but not sig­nif­i­cant.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.